| Literature DB >> 28984820 |
Mohammad Golam Mostafa1, Zarat Jahin Queen2, Nicola Cherry3.
Abstract
Arsenic in drinking water is causally linked with cancer of the skin, lung, and urinary bladder, but there is very little data on a possible role for arsenic in the etiology of cervical cancer, a disease in which human papilloma virus is held to be a necessary but not sufficient cause. All histopathology results from cervical specimens from the National Institute of Cancer Research and Hospital (NICRH), Dhaka (1997-2015), and the Anowara Medical Services (2003-2015), both serving the whole of Bangladesh, were classified by cell type. Arsenic concentrations in well water in the thana of residence were estimated from systematic sampling carried out by the British Geological Survey. In a case-referent analysis arsenic estimates for cases of cervical cancer were compared with those found to have benign lesions. In this study, 3464 NICRH (CH) cervical specimens and 30,050 community medical service (CMS) specimens were available: 3329 (CH) and 899 (CMS) were recorded as malignant. Most were squamous cell carcinoma, of which 4.9% were poorly differentiated. Overall, there was no increase in cervical cancer with increasing arsenic concentration. Among those with squamous cell histology, a strong dose response was seen for poorly differentiated cancer with increasing arsenic exposure. The odds ratio increased monotonically, compared with exposure <10 μg/L, from 1.58 at 10 < 50 μg/L to 8.11 at >200 μg/L (p < 0.001). Given the high proportion of Bangladeshis using drinking water containing >50 μg/L of arsenic, the evidence that arsenic is implicated in cancer grade suggests a need for further investigation and the introduction of cervical screening in high arsenic areas.Entities:
Keywords: Bangladesh; arsenic; cervical cancer; epidemiology; poorly differentiated squamous cell
Mesh:
Substances:
Year: 2017 PMID: 28984820 PMCID: PMC5664686 DOI: 10.3390/ijerph14101185
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Figure 1Study population.
Histopathology of malignant cases with mean age and year of diagnosis.
| Cancer Hospital | Community Medical Service | |||||||
|---|---|---|---|---|---|---|---|---|
| N | % within Malignant | Mean Age (SD) | Mean Year (SD) | N | % within Malignant | Mean Age (SD) | Mean Year (SD) | |
| Benign | 85 | - | 38.8 (9.3) | 2013.5 (1.2) | 28,345 | - | 43.5 (9.4) | 2010.0 (3.1) |
| Dysplasia (CIN) | 50 | - | 44.9 (10.1) | 2012.6 (2.1) | 806 | - | 43.1 (9.6) | 2009.9 (1.9) |
| Squamous cell: | ||||||||
| well differentiated | 2913 | 87.5 | 48.9 (11.2) | 2007.5 (5.1) | 724 | 80.5 | 47.0 (11.0) | 2010.8 (4.1) |
| poorly differentiated | 163 | 4.9 | 49.0 (11.9) | 2005.3 (4.7) | 24 | 2.7 | 48.4 (10.4) | 2009.8 (5.0) |
| Adenocarcinoma | 206 | 6.2 | 44.5 (11.2) | 2007.3 (5.2) | 108 | 12.0 | 48.5 (9.9) | 2010.6 (4.2) |
| Other malignancy | 47 | 1.4 | 49.0 (12.2) | 2010.3 (4.1) | 43 | 4.8 | 46.5 (10.7) | 2011.9 (4.1) |
| 3329 | 100.0 | 48.7 (11.3) | 2007.4 (5.1) | 899 | 100.0 | 47.7 (10.8) | 2010.8 (4.1) | |
| 3464 | 48.4 (11.4) | 2007.6 (5.2) | 30,050 | 100.0 | 47.7 (10.8) | 2010.8 (4.1) | ||
Arsenic concentration by diagnosis.
| Arsenic Concentration (μg/L) | Compared with Benign Cervix | Compared with Benign Renal | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| <10 | 10 < 50 | 50 < 100 | ≥100 | Overall | Test for Linearity | Test for Linearity | ||||||
| N | % | N | % | N | % | N | % | N | % | |||
| Benign | 13 | 15.3 | 43 | 50.6 | 15 | 17.6 | 14 | 16.5 | 85 | 100 | - | - |
| Dysplasia (CIN) | 15 | 30.0 | 16 | 32.0 | 7 | 14.0 | 12 | 24.0 | 50 | 100 | 0.856 | 0.846 |
| Squamous cell: | ||||||||||||
| well differentiated | 1144 | 39.3 | 907 | 31.1 | 382 | 13.1 | 480 | 16.5 | 2913 | 100 | 0.017 | 0.005 |
| poorly differentiated | 33 | 20.2 | 33 | 20.2 | 26 | 16.0 | 71 | 43.6 | 163 | 100 | 0.002 | 0.000 |
| Adenocarcinoma | 79 | 38.3 | 49 | 23.8 | 29 | 14.1 | 49 | 23.8 | 206 | 100 | 0.408 | 0.661 |
| Other malignant | 13 | 27.7 | 19 | 40.4 | 9 | 10.1 | 6 | 12.8 | 47 | 100 | 0.292 | 0.543 |
| All malignant | 1269 | 38.1 | 1008 | 30.3 | 446 | 13.4 | 606 | 18.2 | 3329 | 100 | 0.052 | 0.031 |
| All | 1297 | 37.4 | 1067 | 30.8 | 468 | 13.5 | 632 | 18.2 | 3464 | 100 | - | - |
| Benign | 9172 | 32.4 | 8970 | 31.6 | 3774 | 13.3 | 6429 | 22.7 | 28,345 | 100 | - | - |
| Dysplasia (CIN) | 250 | 31.0 | 259 | 32.1 | 112 | 13.9 | 185 | 23.0 | 806 | 100 | 0.544 | 0.963 |
| Squamous cell: | ||||||||||||
| well differentiated | 215 | 29.7 | 238 | 32.9 | 116 | 16.0 | 155 | 21.4 | 724 | 100 | 0.509 | 0.930 |
| poorly differentiated | 8 | 33.3 | 11 | 45.8 | 1 | 4.2 | 4 | 16.7 | 24 | 100 | 0.340 | 0.341 |
| Adenocarcinoma | 42 | 38.9 | 35 | 32.4 | 13 | 12.0 | 18 | 16.7 | 108 | 100 | 0.071 | 0.109 |
| Other malignant | 14 | 32.6 | 22 | 51.2 | 6 | 14.0 | 1 | 2.3 | 43 | 100 | 0.020 | 0.027 |
| All malignant | 279 | 31.0 | 306 | 34.0 | 136 | 15.1 | 178 | 19.8 | 899 | 100 | 0.495 | 0.575 |
| All | 9701 | 32.3 | 9535 | 31.7 | 4022 | 13.4 | 6792 | 22.6 | 30,050 | 100 | - | - |
| Females with benign renal lesions | 79 | 35.6 | 58 | 26.1 | 28 | 12.6 | 57 | 25.7 | 222 | 100 | - | - |
* χ2 = 120.96 p = 0.000, ** χ2 =26.62 p = 0.032.
Logistic regression * for well differentiated squamous cell, poorly differentiated squamous cell and all malignancies by arsenic concentration with benign renal lesions as the comparison group.
| Arsenic Concentration (μg/L) | Squamous Cell | All Malignancies | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Well Differentiated | Poorly Differentiated | |||||||||||
| Cancer Hospital | Both Series | Cancer Hospital | Both Series | Cancer Hospital | Both Series | |||||||
| OR | 95% CI | OR | 95% CI | OR | 95% CI | OR | 95% CI | OR | 95% CI | OR | 95% CI | |
| <10 | 1 | - | 1 | - | 1 | - | 1 | - | 1 | - | 1 | - |
| 10 < 50 | 1.07 | 0.61–1.86 | 1.15 | 0.67–1.96 | 1.37 | 0.51–3.69 | 1.52 | 0.60–3.86 | 1.05 | 0.61–1.81 | 1.18 | 0.70–2.01 |
| 50 < 100 | 0.90 | 0.45–1.81 | 1.04 | 0.51–2.10 | 3.42 | 1.09–10.70 | 2.74 | 0.91–8.23 | 0.99 | 0.49–1.98 | 1.10 | 0.55–2.20 |
| ≥100 | 0.42 | 0.22–0.79 | 0.46 | 0.24–0.87 | 4.98 | 1.92–12.96 | 3.74 | 1.51–9.23 | 0.49 | 0.26–0.91 | 0.51 | 0.27–0.97 |
* Allowing for clustering within thana.
Proportion of squamous cell lesions that are poorly differentiated by arsenic concentration.
| Arsenic Concentration | Cancer Hospital | Community Medical Service | All | ||||||
|---|---|---|---|---|---|---|---|---|---|
| (μg/L) | n | % | N | n | % | N | n | % | N |
| <10 | 33 | 2.8 | 1177 | 8 | 3.6 | 223 | 41 | 2.9 | 1400 |
| 10 < 50 | 33 | 3.5 | 940 | 11 | 4.4 | 249 | 44 | 3.7 | 1189 |
| 50 < 100 | 26 | 6.4 | 408 | 1 | 0.9 | 117 | 27 | 5.1 | 525 |
| 100 < 200 | 37 | 11.3 | 328 | 4 | 3.7 | 107 | 41 | 9.4 | 435 |
| ≥200 | 34 | 15.2 | 223 | 0 | 0.0 | 52 | 34 | 12.4 | 375 |
| Overall | 163 | 5.3 | 3076 | 24 | 3.2 | 748 | 187 | 4.9 | 3834 |
| Test for linearity | χ2 = 80.75 | χ2 = 1.57 | χ2 = 60.82 | ||||||
Logistic regression for histological diagnosis of poorly differentiated squamous cell carcinoma, allowing for clustering within thana (N = 3824).
| Arsenic Concentration (μg/L) | Odds Ratio | 95% Confidence Interval |
|---|---|---|
| <10 | 1 | - |
| 10 < 50 | 1.58 | 0.89–2.80 |
| 50 < 100 | 2.61 | 1.35–5.00 |
| 100 < 200 | 4.56 | 2.47–8.42 |
| ≥200 | 8.11 | 4.08–16.15 |
| Source of specimen: | ||
| cancer hospital | 1.97 | 1.20–3.21 |
| Age (continuous) | 1.01 | 0.99–1.02 |
| Year of diagnosis: | ||
| Before 2010 | 3.26 | 2.28–4.66 |